Can a Pre-Dose prevent a dangerous reaction in multiple myeloma treatment?

NCT ID NCT07609940

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study tests whether giving tocilizumab before the first dose of linvoseltamab can lower the risk of cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma. The 30 participants have already tried at least four prior treatments. Researchers will monitor CRS severity, hospital visits, and side effects to see if this approach is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tocilizumab and linvoseltamab
What this could lead to: If it works, this could make a new multiple myeloma treatment safer by reducing a serious side effect called cytokine release syndrome.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The approach may not reduce side effects as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytokine release syndrome plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Contacts and locations

Locations

Mary Bird Perkins Cancer Center
RECRUITING

Baton Rouge, Louisiana, 70809, United States
Northwest Medical Specialties, PLLC
RECRUITING

Tacoma, Washington, 98405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.